<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177719</url>
  </required_header>
  <id_info>
    <org_study_id>00908</org_study_id>
    <nct_id>NCT04177719</nct_id>
  </id_info>
  <brief_title>Neurobiological Effects of Oxytocin in Schizophrenia</brief_title>
  <official_title>Understanding the Neurobiological Effects of Oxytocin on Social Trust Deficits in Schizophrenia: A Multimodal Imaging - Genetics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health and Neuro Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health and Neuro Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      22 male patients with schizophrenia and 22 male healthy volunteers will be included in the
      study. Subjects who meet the inclusion and exclusion criteria for the study will be
      recruited. After completion of clinical assessments and neuropsychological assessments, all
      subjects will undergo two multi-modal imaging sessions. In one scan they will receive
      intranasal oxytocin and in another scan will receive intranasal saline as control. The order
      of administration of the medication will be counterbalanced and subjects will be blind to the
      medication administered. Using the simultaneous PET-MRI scanner, PET and fMRI data will be
      collected simultaneously. Blood will be collected for analysis of oxytocin receptor gene
      polymorphism and its potential effect on brain activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET</measure>
    <time_frame>90 minues</time_frame>
    <description>changes in [18F] flumazenil specific binding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI changes</measure>
    <time_frame>90 minutes</time_frame>
    <description>changes in brain functional connectivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MRS</measure>
    <time_frame>90 minutes</time_frame>
    <description>Changes in brain chemistry measured using MRS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose oxytocin or placebo will be given intranasally. The order of administration will be counterbalanced</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single-dose oxytocin or placebo will be given intranasally. The order of administration will be counterbalanced</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>oxytocin or placebo will be given intranasally. The order of administration will be counterbalanced</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Schizophrenia group

        Inclusion Criteria:

          1. Diagnosis of schizophrenia or schizoaffective disorder

          2. Males between 18 and 45 years

          3. capacity to provide informed consent

        Exclusion Criteria:

          1. current comorbid axis I diagnosis and no alcohol/substance abuse/dependence in the
             last 12 months (except nicotine)

          2. Contraindication to oxytocin like hypersensitivity, vascular disease, chronic
             nephritis, epilepsy, asthma

          3. Contraindication to MRI like implants/claustrophobia

          4. Past history of head injury resulting in loss of consciousness or neurosurgery

          5. Concomitant severe medical conditions

          6. On treatment with benzodiazepine medications for at least 8 weeks

          7. Contraindication to Positron emission tomography

        Healthy volunteers

        Inclusion Criteria:

          1. Males between 18 and 45 years

          2. capacity to provide informed consent

        Exclusion Criteria:

          1. Lifetime diagnosis of psychiatric illness including substance dependence

          2. contraindication to oxytocin like hypersensitivity, vascular disease, chronic
             nephritis, epilepsy, asthma

          3. contraindication to MRI like implants/claustrophobia

          4. past history of head injury resulting in loss of consciousness or neurosurgery

          5. concomitant severe medical conditions

          6. on treatment with benzodiazepine medications for at least 8 weeks

          7. contraindication to Positron emission tomography

          8. Family history of schizophrenia, schizoaffective or schizophreniform disorder in
             family member
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Naren P Rao, MD</last_name>
    <phone>08026995879</phone>
    <email>narenrao@nimhans.ac.in</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Mental Health and Neurosciecnes</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naren P Rao, MD</last_name>
      <phone>08026995879</phone>
      <email>narenrao@nimhans.ac.in</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health and Neuro Sciences, India</investigator_affiliation>
    <investigator_full_name>Dr Naren P Rao</investigator_full_name>
    <investigator_title>Additional Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

